Leap Therapeutics Q2 net loss $20.4M; DKN-01 ORR 33% in CRC; $40M PIPE completed

CYPHERPUNK TECHNOLOGIES INC.

2024-Q2 EPS reported -$1.01

Net loss of $20.4M in Q2 2024 vs $13.4M in Q2 2023; R&D expenses rose to $17.9M on trial costs.
DKN-01 combo achieved 33% ORR (38% left-sided) in Part A of DeFianCe CRC study; median PFS 6.3 months.
Enrollment in Part B expanded to 180 patients; completion expected Sept 2024, data mid-2025.
DisTinGuish Part C gastric/GEJ cancer data expected Q4 2024 or early 2025.
Completed $40M private placement with Gilead, Samsara, others; cash $78.5M funds into Q2 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.